Asia FX steady as Fed, BOJ rate decisions loom; US-China talks in focus
Dawn Christine Maroney, the President of Alignment Healthcare, Inc. (NASDAQ:ALHC), recently sold shares of the company’s stock, according to a filing with the Securities and Exchange Commission. The transaction comes as ALHC trades near its 52-week high of $17.27, having delivered an impressive 258.87% return over the past year. The transactions, which took place on March 18 and 19, involved the sale of a total of 43,649 shares, amounting to approximately $729,161.
The sales were executed at a weighted-average price range of $16.088 to $16.9588 per share. These transactions were necessary for Maroney to cover tax withholding obligations related to vested stock grants and restricted stock units. Following these sales, Maroney retains ownership of 2,374,051 shares of Alignment Healthcare’s common stock.
The sales were not discretionary trades, as they were required to meet tax obligations associated with recently vested stock awards.
In other recent news, Alignment Healthcare Inc. has reported a strong fourth quarter for 2024, surpassing analysts’ expectations with an earnings per share (EPS) of -0.16 compared to the forecast of -0.18. The company’s revenue also exceeded projections, reaching $701.2 million against the expected $674.97 million. Raymond (NSE:RYMD) James analyst John Ransom responded to these results by increasing the price target for Alignment Healthcare to $19.00, up from $14.00, while maintaining a Strong Buy rating. Additionally, Piper Sandler raised its target price to $21.00, highlighting confidence in the company’s growth potential and maintaining an Overweight rating.
The company demonstrated significant membership growth of approximately 59% in 2024, with a notable expansion outside California. This growth contributed to a 48% year-over-year increase in total revenue, reaching $2.7 billion. Alignment Healthcare’s adjusted EBITDA also turned positive for the first time, marking a key milestone. For 2025, the company has provided guidance for revenue between $3.72 billion and $3.78 billion, with adjusted gross profit expected to range from $415 million to $445 million.
The company’s ability to maintain high STAR ratings has been emphasized as a critical factor in its success, contributing to better member retention and lower customer acquisition costs. Analysts from both Piper Sandler and Raymond James have expressed optimism about Alignment Healthcare’s future, citing its scalable business model and strategic expansion into new markets.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.